In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19

Gabriel M Aisenberg

doi:10.7326/J22-0056

In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19

Ann Intern Med. 2022 Aug;175(8):JC92. doi: 10.7326/J22-0056. Epub 2022 Aug 2.

Author

Gabriel M Aisenberg¹

Affiliation

¹ University of Texas, Houston, Houston, Texas, USA (G.M.A.).

PMID: 35914259
DOI: 10.7326/J22-0056

Abstract

Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188-200. 35443106.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Neutralizing
COVID-19* / prevention & control
Drug Combinations
Humans
Vaccination

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Drug Combinations
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab